Biotech News

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics (BJDX)Bluejay Diagnostics2026-06-25 13:46 ESTCompany update

ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives

Open original release

Related news

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

BJDXBluejay Diagnostics2026-06-25 13:46 EST

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

View all latest news

Bluejay Diagnostics

Bluejay Diagnostics is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.

Recent company news

BJDXBluejay Diagnostics2026-06-26 12:02 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-26 12:02 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-26 12:02 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BJDXBluejay Diagnostics2026-06-26 12:02 EST

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

BJDXBluejay Diagnostics2026-06-26 12:02 EST

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States